Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma

Li, Xiuqin; Zhang, Shulan; Cai, Zhen; Zhou, Yuan; Ye, Tian-Min; Chiu, Jen‐Fu

doi:10.1016/j.canlet.2008.10.019

Cited by 19 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the relatively small number of tissue and ascites specimens studied, the majority of proteins identified in the present study as being significantly differentially secreted from malignant and CTRL cell samples had been detected in previous studies (8)(9)(10)(11)(12)(13)(14)(15)(16), confirming their potent and important role. To the best of our knowledge, proteins including HSP-10 and DKK3, had not previously been identified by a proteomic approach, but had been suggested as potent markers using alternate approaches (19,30); however the present study was unable to confirm their utility as biomarkers of serous ovarian cancer by the immunological method.…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

et al. 2017

View full text Add to dashboard Cite

Abstract. Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription-quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 76%

“…Certain previous studies have analyzed the proteomic profiles of ovarian tumor tissues, cell lines, urine, ascites fluid and blood samples (8)(9)(10)(11)(12)(13)(14). Analysis of the ovarian cancer cell line secretome has also provided information on potential markers (11,15).…”

Section: Introductionmentioning

confidence: 99%

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

et al. 2017

View full text Add to dashboard Cite

show abstract

“…PRDX3 is an active responder to oxidative stress, and its expression of concordantly augmented to remove cellular ROS and inhibit apoptosis, which is beneficial to cancer growth and invasion. Furthermore, short hairpin RNA (shRNA)-mediated loss in functional PRDX3 expression led to significant suppression of migration and transendothelial invasion in MCF-7 breast cancer cells in vitro and significant inhibition of breast cancer metastasis in vivo (Kim et al, 2009;Li et al, 2009;Liu et al, 2010;Wu et al, 2010). Recently, abundant evidence has also confirmed that tissue-specific expression of PRDX3 plays an important role in hepatocarcinoma progression (Dai et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Shi¹,

Wu²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Recently, peroxiredoxin3 (PRDX3) was identified as a novel molecular marker for the progression of hepatocellular carcinoma (HCC). However, its potential clinical application as a serum marker for the early diagnosis and prognosis of HCC has not been investigated. Methods: PRDX3, alpha-fetaprotein (AFP), and other biochemical parameters were measured in serum samples from 297 Chinese patients, including 96 with HCC, 98 with liver cirrhosis (LC), and 103 healthy controls (HCs). Correlations between serum PRDX3 expression and clinicopathological variables and the relationship between serum PRDX3 expression and prognosis were analyzed. Results: Serum PRDX3 was significantly higher in HCC patients than in the LC and HC groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 85.9% and 75.3%, respectively, at a cutoff of 153.26 ng/mL, and the area under the curve was 0.865. Moreover, serum PRDX3 expression was strongly associated with AFP level, tumor diameter, TNM stage, and portal vein invasion. Kaplan-Meier curve analysis revealed that HCC patients with high serum PRDX3 expression had a shorter median survival time than those with low PRDX3 expression. Moreover, serum PRDX3 expression was an independent risk factor for overall survival. The inverse correlation between serum PRDX3 and patient survival remained significant in patients with early-stage HCC and in those with normal serum AFP levels. Conclusions: Serum PRDX3 can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC.

show abstract

“…In addition, the overexpression of PRDX3 had also been found in cervical cancer, colorectal cancer and ovarian serous cystadenocarinoma. (25,28,29). However, there are few reports on the relationship between PRDX3 and the progression of HCC, and thus, we focused on the study of thioredoxin-dependent peroxide reductase PRDX3.…”

Section: Discussionmentioning

confidence: 99%

Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach

et al. 2012

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis due to resistance to conventional chemotherapy and limited efficacy of radiotherapy. Thus, alternative therapeutic strategies need to be established. In order to search for a useful biomarker to improve its efficacy, we conducted a two-dimensional gel electrophoresis and MALDI-TOF MS-based comparative proteomic analysis to profile the differentially expressed proteins between HCC tumor tissues with histological evidence and the adjacent non-tumor tissues. Twenty-two out of 43 dysregulated proteins were identified, including 15 upregulated proteins, and 7 downregulated proteins (over 2-fold, P<0.01). The expression of peroxiredoxin 3 (PRDX3) at the mRNA and protein levels was confirmed by RT-PCR and western blotting in HCC cell lines, and HCC samples, and further analysed by immunohistochemistry in HCC samples of different clinical pathological stages. The results indicated that overexpression of PRDX3 was associated with 94.9% HCC, and correlated with poor differentiation (P<0.05), which suggest that PRDX3 has substantial clinical impact on the progression of hepatocarcinoma, and may be a potential therapeutic target for HCC.

show abstract

Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma

Cited by 19 publications

References 42 publications

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight

Serum Peroxiredoxin3 is a Useful Biomarker for Early Diagnosis and Assessemnt of Prognosis of Hepatocellular Carcinoma in Chinese Patients

Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach

Contact Info

Product

Resources

About